Developing the next generation bacterial cancer therapy
T3 Pharmaceuticals AG
Incorporated
06.05.2015Headquarters
AllschwilSupport
The vision of T3 Pharmaceuticals Ltd is to improve the lives of cancer patients by developing very specific and efficient therapies using live bacteria. The Company was founded in May 2015 as a spin-off of the University of Basel. T3 Pharma is developing an efficient protein delivery technology that is based on the use of live bacteria expressing the type 3 secretion system. While the technology has a wide spectrum of applications in drug development, T3 Pharma has been advancing the platform as a novel therapeutic approach to treat solid tumors.
News
T3 Pharma acquired by Boehringer Ingelheim for CHF 450 Million to strengthen immuno-oncology portfolio (venturelab.swiss)
Boehringer Ingelheim acquires T3 Pharma for up to CHF450 million (startupticker.ch)
Swiss Accelerator: Innosuisse supports 53 companies with CHF112 million (startupticker.ch)
Fünf Unternehmerinnen und Unternehmer am SEF 2021 ausgezeichnet (startupticker.ch)
On a growth path: Switzerland’s most promising scale-ups in 2021 (TOP 100)
Die Finalisten des Swiss Economic Award stehen fest (startupticker.ch)
T3 Pharma raises CHF 25M to advance bacterial cancer therapy (startupticker.ch)
TOP 100 - Meet the 5 Fast Climbers Startups of 2019 Ranking (venturelab.swiss)
Financing Round Paves the Way for T3 Pharma to Enter the Clinic (startupticker.ch)
CHF 750?000 awarded at the 30th De Vigier 2019 Award ceremony (startupticker.ch)
Drawing closer to the finale of the de Vigier Award (startupticker.ch)
T3 Pharma wins the title ?2018 Science Start-Up of the Year? (startupticker.ch)
BaseLaunch selektiert sechs Startups für zweite Förderphase (startupticker.ch)
BaseLaunch startups: From gene therapies to digital measurement (startupticker.ch)
BaseLaunch startups: From gene therapies to digital measurement (startupticker.ch)
15 Swiss startups to present at Swiss Biotech Day (startupticker.ch)
Milestones news
T3 Pharma closes second financing round to complete the preclinical development of its breakthrough bacteria-based cancer therapy
T3 Pharma's bacteria-based protein delivery technology is published in "The Journal of Cell Biology"
CTI grant - Joint project between T3 Pharma and Prof. Dr. E. Nigg (Biozentrum, University of Basel)
Videos and Presentations
T3 Pharma testimonial film from the Lichtsteiner Foundation
Presentation @Falling Walls Venture 2018
Venture 2016: Company presentation